NEW YORK, Nov. 14 – Orchid BioSciences said Wednesday it had agreed to collaborate with GlaxoSmithKline on a genome-wide SNP-validation program.

Under the terms of the deal, Glaxo will select SNP candidates from Orchid’s database and Orchid will provide high-throughput genotyping information. In addition, Orchid will also develop SNP assays for use in the genome-wide study. 

Financial terms of the deal were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.